epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
pharma · Acne Rosacea · Atopic Dermatitis · DRMA
Dermata Therapeutics
Dermata Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2014 Founded
12 Employees
Public company Type
DRMA · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 12
- Programs
- 4
- Drugs
- 2
- Patents
- 30
Dermata Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dermata Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Dermata Therapeutics in public FDA and regional records.